Clinical trial · NCT07491445
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Sponsor: Revolution Medicines, Inc.
Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Interventions
- daraxonrasib · DRUG
oral tablets
- gemcitabine · DRUG
intravenous (IV) infusion
- nab-paclitaxel · DRUG
IV infusion
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent. * Documented RAS mutation status, either mutant or wild-type. * Measurable disease per RECIST v1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Able to take oral medications. Exclusion Criteria: * Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting. * Active or known history of untreated central nervous system metastatic disease. * Any conditions that may affect the ability to take or absorb study drug. * Major surgery within 28 days prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Sites (49)
- Mayo Clinic - Scottsdale, Phoenix, Arizona · Recruiting
- Honor Health Research Institute, Scottsdale, Arizona · Recruiting
- University of California Los Angeles Health - Hematology/Oncology, Los Angeles, California · Recruiting
- University of California San Francisco, San Francisco, California · Recruiting
- Mayo Clinic Cancer Center- Florida, Jacksonville, Florida · Recruiting
- H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida · Recruiting
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland · Recruiting
- Dana-Farber Cancer Institute, Boston, Massachusetts · Recruiting
- Mayo Clinic Cancer Center- Rochester, Rochester, Minnesota · Recruiting
- Comprehensive Cancer Centers of Nevada, Henderson, Nevada · Active, not recruiting
- Memorial Sloan Kettering Cancer Center, New York, New York · Recruiting
- Duke University Medical Center, Durham, North Carolina · Recruiting
- University of Cincinnati Cancer Center, Cincinnati, Ohio · Recruiting
- Taylor Cancer Research Center, Maumee, Ohio · Active, not recruiting
- SCRI Oncology Partners, Nashville, Tennessee · Recruiting
- SCRI - Texas Oncology Dallas, Dallas, Texas · Recruiting
- MD Anderson Cancer Center, Houston, Texas · Recruiting
- Huntsman Cancer Institute, Salt Lake City, Utah · Recruiting
- Virginia Cancer Specialists, Fairfax, Virginia · Recruiting
- Virginia Mason Medical Center, Seattle, Washington · Recruiting
- Prince of Wales Hospital, Randwick, New South Wales · Recruiting
- Calvary Mater Newcastle, Waratah, New South Wales · Recruiting
- Epworth HealthCare, East Melbourne, Victoria · Recruiting
- Krankenhaus der Barmherzigen Brüder Wien-Klinisch wissenschaftliche Studien, Vienna, Austria · Recruiting
- CEPON - Centro de Pesquisa Oncologicas de Santa Catarina, Florianópolis, Santa Catarina · Recruiting
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, São Paulo, Brazil · Recruiting
- Princess Margaret Cancer Centre, Toronto, Ontario · Recruiting
- McGill University - Dept. Oncology Clinical Research Program, Montreal, Quebec · Recruiting
- National Cancer Center - East, Kashiwa, Chiba · Recruiting
- Cancer Institute Hospital - Japan Foundation for Cancer Research, Koto-Ku, Tokyo · Recruiting
- Chiba Cancer Center, Chiba, Japan · Recruiting
- NHO Kyushu Cancer Center, Fukuoka, Japan · Recruiting
- Kyushu University Hospital, Fukuoka, Japan · Recruiting
- Kanagawa Cancer Canter, Kanagawa, Japan · Recruiting
- Osaka International Cancer Institute, Osaka, Japan · Recruiting
- National Cancer Center - Tokyo, Tokyo, Japan · Recruiting
- Wakayama Medical University Hospital, Wakayama, Japan · Recruiting
- Yamaguchi University Hospital, Yamaguchi, Japan · Recruiting
- Curie Oncology Pte Ltd, Singapore, Singapore · Recruiting
- Seoul National University Hospital, Seoul, South Korea · Recruiting
- Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan · Recruiting
- China Medical University Hospital, Taichung, Taiwan · Recruiting
- National Taiwan University Hospital, Taipei, Taiwan · Recruiting
- Torbay Hospital, Torquay, Devon · Recruiting
- Queen Elizabeth Hospital - Birmingham, Birmingham, United Kingdom · Recruiting
- NHS Cambridge of Addenbrooke Hospital, Cambridge, United Kingdom · Recruiting
- Barts Hospital, London, United Kingdom · Recruiting
- Royal Marsden Hospital - London, London, United Kingdom · Recruiting
- The Christie NHS Foundation Trust, Manchester, United Kingdom · Recruiting
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-09-14.